Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Dr Sara M. Tolaney on Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer
August 08, 2018
Dr Dennis P. Scanlon on Recent Attempts to Address Clinician Burnout
August 06, 2018
Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic
July 27, 2018
Dr Michael Thompson Outlines Challenges With the Mass Adoption of EHRs, Precision Medicine
July 25, 2018
Currently Reading
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer
July 23, 2018
Where Dr Victoria Villaflor Thinks the Future of Precision Medicine Is Headed
July 08, 2018
Dr Peter Paul Yu on Progress in the Move Toward Interoperability
July 06, 2018
Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting
July 05, 2018
Leonard Saltz: Novel Approaches to Colon Cancer, Behaviors That Impact Survival
July 02, 2018
Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer
June 28, 2018
Dr Victoria Villaflor Discusses How Novel Therapies Have Changed Cancer Treatment
June 26, 2018
Dr Peter Paul Yu: How Next-Generation Sequencing is Changing Cancer Care
June 21, 2018
Dr James Lin Chen on the Shift to Precision Medicine
June 18, 2018
Ellen Miller Sonet: The Importance of Cancer Care Providers Informing Patients of Treatment Costs
June 17, 2018
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16, 2018
Dr Leonard B. Saltz: The Role of Next-Generation Sequencing in Advancing Precision Medicine
June 14, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018

Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, outlines the role of adjuvant therapy in treating patients with HER2-positive breast cancer, as well as the absence of biomarkers in this patient population.


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, outlines the role of adjuvant therapy in treating patients with HER2-positive breast cancer, as well as the absence of biomarkers in this patient population.

Transcript

What role does adjuvant treatment play in the treatment of HER2-positive breast cancer?

I think the landscape in the adjuvant setting has also changed. Typically, the way we had previously approached patients with HER2-positive disease had been to either give a regimen called AC chemotherapy, followed by a taxane and Herceptin, or we would give a non-anthracycline-based therapy, which we call TCH, so using a docetaxel with carboplatin and trastuzumab. But, now we’ve seen introduction of a few new HER2 agents into the early-stage setting, one being pertuzumab.

So, there’s the APHINITY data that came out last year that showed that when you add pertuzumab to standard chemotherapy with trastuzumab, it resulted in an improvement in disease-free survival. That being said, that improvement was pretty small and seemed to be greater in patients who had higher risk disease. So, patients, for example, who had either node-positive disease or hormone-receptor-negative disease. So, at this point in time, we are, generally, incorporating pertuzumab into patients who have higher risk for HER2- positive disease.

One other agent we’re also including is neratinib, and this is a potent tyrosine kinase inhibitor against HER1, HER2, and HER4. This agent was studied in the exteNET trial, which looked at patients who had completed a year of trastuzumab based therapy, and then they got randomized to get a year of neratinib or nothing. They found that getting a year of neratinib, after completion of your year of trastuzumab, did provide additional benefit, but the benefit was really seen in the hormone-receptor-positive patients.

So, we do think about using neratinib in someone who had a particularly high-risk ER-positive tumor. I will said, that being said, the patients that were enrolled onto exteNET were all pertuzumab naïve, and now that we’re starting to integrate pertuzumab into adjuvant therapy, we really don’t have data about what the benefits are for using neratinib in someone who’s had prior pertuzumab.

Are there any identified biomarkers that guide a treatment approach for these patients?

Not at this time. I wish, but there aren’t any defined biomarkers that can help us predict which patients are likely to benefit from which treatment. I think where it would be particularly beneficial to us would be in trying to decide which patients are going to benefit from pertuzumab because the absolute benefit was small, then, I think there’s likely to be greater benefit in patients who may have certain biological predisposition to getting benefit from pertuzumab. So, there is ongoing work trying to look at biomarker predictors from the affinity trial that we’re waiting.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!